Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos to Participate in Upcoming Investor Conferences
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Satellos to Participate in Upcoming Investor Conferences
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
Satellos to Participate in December Investor Conferences
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy
Satellos to Participate in Four September Institutional and Retail Investor Conferences
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
Satellos Bioscience Shareholders Elect Two New Board Members
Satellos Bioscience to Participate in PPMD's Annual Conference in Las Vegas
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants
Satellos to Present at the CureDuchenne FUTURES National Conference
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
Satellos to Participate in Two April Investor Conferences
Satellos Reports 2024 Financial Results and Highlights Company Progress
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
Satellos Announces Closing of US$40M Public Offering
Satellos Announces Pricing of US$40M Overnight Marketed Public Offering
Satellos Announces Overnight Marketed Public Offering of Common Shares
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
Satellos to Participate in November 2024 Investor Conferences
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy